M&A / Deals AZ forges ever-closer ties with China’s CSPC Pharma PharmaphorumAstraZeneca has returned to China's CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaphorum AstraZeneca has returned to China’s CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche’s KRAS drug tops its rivals in lung cancer trialNext: Novartis receives European Commission approval for Itvisma for spinal muscular atrophy Related Stories M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover pharminent July 22, 2026 M&A / Deals Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics pharminent July 20, 2026 M&A / Deals Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal pharminent July 20, 2026
